RoxyBond Rival Can't Use Suit To Delay Sales, FDA Says
By Dani Kass ( August 25, 2017, 8:22 PM EDT) -- Pharmaceutical Manufacturing Research Services Inc. can't use a suit challenging how quickly the U.S. Food and Drug Administration responded to safety concerns it raised in citizen petitions to effectively delay a competitor coming on the market with its abuse-deterrent opioid RoxyBond, the agency told a Pennsylvania federal court Thursday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.